NodThera

Our management team will attend the Piper Sandler 36th Annual Healthcare Conference, happening from 3-5 December in New York City. The conference offers a valuable opportunity for one-on-one meetings, as we share NodThera’s vision for revolutionizing treatment of #cardiometabolic and #neurodegenerative diseases. With our cutting-edge #NLRP3 #inflammasome-targeting approach, we’re paving the way for next-generation therapies that address chronic inflammation at its source. Let’s connect to discuss how #innovation can transform patient outcomes. #Networking #NodThera #NLRP3 #Biotech #Conference

Great article from David Wild, ‘The Future of Inflammation: The Inflammasome and Beyond,’ which highlights the game-changing potential of #NLRP3 #inflammasome inhibitors, offering hope not only for conventional inflammatory conditions but also for #cardiovascular health, metabolic issues like #obesity, and even #neurodegenerative diseases. There has been a paradigm shift in thinking about #inflammation, now understood to be a key driver of conditions not conventionally considered as inflammatory. In David’s article, Alan Watt, NodThera’s President and Chief Scientific Officer, shares how we're pioneering targeted NLRP3 inhibition to address chronic inflammation precisely where it’s needed — without compromising the body’s essential defence mechanisms. To learn more about our approach, including plans for further #ClincialDevelopment, read the full article here: https://lnkd.in/eE_i2Tte #Biotech #Neuroinflammation #DrugDiscovery 

On Monday, 18 November, NodThera’s management team will be on the ground in London, UK to participate in one-to-one meetings with #investors and potential partners at the LifeSci Capital LLC and Sofinnova Partners Growth & Innovation Summit. Alongside 30 of the most promising #LifeSciences international innovators, we look forward to discussing our work developing therapeutics that target the #NLRP3 #inflammasome to tackle conditions caused by chronic #inflammation, including cardiometabolic and neurodegenerative diseases. If you are also attending and interested in learning more about our innovative approach that has the potential to shape the future of #healthcare, please reach out to set up a meeting. For more information: https://lnkd.in/efW9BQfx #NodThera #Inflammasome #Biotech #Networking #Innovation

Thrilled to share that NodThera's management will be participating in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, held virtually on October 22-23. This is a valuable opportunity to dive into NodThera's latest advancements in NLRP3 inflammasome inhibition and our innovative approach to tackling chronic inflammation. We’re excited to connect with investors who share our vision for transforming how cardiometabolic and neurodegenerative diseases are treated and unlocking the potential of next-generation therapies. #Networking #NodThera #NLRP3 #inflammation #Innovation #Biotech

We had the pleasure of attending the Fierce Biotech Summit in Boston last week, where our CEO, Daniel Swisher, and CFO/CBO, Greg Chow, proudly accepted our #Fierce15 award! 🏆 Thank you to the Fierce team and everyone involved for hosting a great event, and congratulations to all the other #Fierce15 2024 winners! We are excited to be in such great company, shaping the future of biotech together. #NodThera #Award #Innovation #Biotech #NLRP3 #CardiovascularDisease #Obesity #Neuroinflammation

A recent article in The New York Times highlights a groundbreaking perspective on #inflammation as a key driver of various diseases, from heart disease to dementia. As the understanding of inflammation evolves, so does our approach to managing it. At NodThera, we are at the forefront of this transformation. Our work focuses on developing innovative therapeutics that precisely target #NLRP3 #inflammasome to tackle chronic conditions without compromising the body's essential defense mechanisms. We aim to bring a new class of anti-inflammatory drugs to market that can address the “silent” yet detrimental effects of chronic inflammation while preserving the balance necessary for overall health. The future of medicine is not about eliminating inflammation but managing it intelligently to enhance patient outcomes. We're excited to be part of this journey, leveraging our cutting-edge research to develop novel therapies that can potentially transform how we treat a myriad of conditions linked to chronic inflammation. Read the full NYT article here: https://lnkd.in/dN_irKBy

Spotted on the trading floor at the NYSE! Great to see NodThera on the screens at the New York Stock Exchange following our inclusion in Fierce Biotech's ‘Fierce 15’ 2024 special report. #NodThera #Fierce15 #Innovation #NYSE #Biotech #NLRP3

We are delighted to have been named by Fierce Biotech as one of its ‘Fierce 15’, in the 2024 special report highlighting the most innovative and promising #biotech companies in the industry. This recognition follows the significant progress we have made towards realizing the full potential of targeting the #NLRP3 #inflammasome and our bright future as we progress the clinical development programs in #CardiovascularDisease, #Obesity and #Neuroinflammation. Learn more about why we stand out here: https://lnkd.in/eXVdVv4z #NodThera #Fierce15 #Innovation 

Please join us in extending a warm welcome to Greg Chow, NodThera’s new Chief Financial and Business Officer! Greg brings over 25 years of public and private company leadership experience, including deep expertise in capital markets, #DrugDevelopment and business development. Over the course of his career, he helped lead the execution of major financing rounds, including a $254 million Series F fundraise at Freenome Holdings, where he most recently served as CFO. Find out more about Greg’s #appointment and experience here: https://lnkd.in/e6RMyFfH #NewHire #NeuroInflammation #WelcomeToTheTeam #NLRP3

We are pleased to share NodThera’s latest research publication detailing the preclinical pharmacology of our clinical-stage drug candidate, NT-0796, which has successfully completed two Ph1b/2a clinical studies in Parkinson’s disease and obese patients at cardiovascular risk. 🔬 Key Highlights: Mechanism of Action: NT-0796 is metabolized by carboxylesterase-1 (CES1) to produce NDT-19795, which inhibits the NLRP3 inflammasome. Potency: In human monocytes/macrophages, NT-0796 demonstrates superior potency compared to NDT-19795 alone. Cellular Dynamics: NT-0796 accumulates rapidly within cells, reaching higher concentrations than those in the medium, followed by conversion to NDT-19795 in CES1-expressing cells. Pharmacodynamics: NT-0796 acts as an effective vehicle to deliver NDT-19795, providing a robust NLRP3 inhibition by leveraging the dynamics of CES1 metabolism. This study underscores our commitment to developing pioneering treatments targeting #NLRP3 #inflammasome-related diseases. Dive into the full study to learn more: https://lnkd.in/eaYk2f5f